Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCT
Background: High-grade serous ovarian cancer (HGSOC) causes 80% of all
ovarian cancer (OC) deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear.
In particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC)
HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and aldehyde
dehydrogenase-1 (ALDH1) CSC biomarker expression in pOC and rOC HGSOCs.
Methods: Two-hundred and twenty-four pOC and rOC intrapatient paired tissue samples